State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S

Sponsor
University of Minnesota (Other)
Overall Status
Withdrawn
CT.gov ID
NCT04011449
Collaborator
(none)
0
1
1
16
0

Study Details

Study Description

Brief Summary

Primary objectives.

The ability of the RC+S to record Local Field Potentials (LFP's) is novel in Deep Brain Stimulation (DBS) technology. The primary goals of this project are to use this function of the RC+S to characterize:

  1. The state- and target-dependency of neuronal oscillations in the subthalamic nucleus (STN), internal globus pallidus (GPi) or external globus pallidus (GPe) of patients with PD,

  2. How these oscillations are altered by levodopa,

  3. The effects of unilateral standard clinical isochronal (e.g. 140 Hz) GPi-, GPe-, and STN-DBS on oscillatory activity and its relationship to the presence and severity of parkinsonian motor signs.

These experiments will leverage the capacity to record LFPs from macroelectrodes implanted in either the GPi/GPe or STN using the Medtronic RC+S DBS system. The long-term goal for this project is to develop closed-loop methods for DBS that are state (resting vs. movement) and movement-phase appropriate.

Secondary objectives.

In addition to establishing the relationship between neural oscillations in the STN, GPi and GPe to clinical and quantitative measures of akinesia, bradykinesia, tremor and rigidity, this project will also examine the relationship of neural oscillations to:

  1. Levodopa-resistant motor features such as postural instability and gait (including freezing of gait),

  2. Response inhibition and impulse control.

Condition or Disease Intervention/Treatment Phase
  • Device: Medtronic RC+S DBS system
N/A

Detailed Description

The Olympus Research System (RC+S) is an implantable pulse generator (IPG) designed to deliver deep brain stimulation (DBS) like a standard clinical neurostimulator, but which allows recordings of local field potential (LFP) activity from the implanted DBS lead.

LFPs are composite electrical signals generated by the brain. They are conventionally divided into frequency bands, as follows: 0-3 Hz (delta), 4-7 Hz (theta), 8-12 Hz (alpha), 13-30 Hz (beta), 31-200 Hz (gamma), and >200 Hz (high frequency). The instantaneous amplitude and power of the LFP recordings are believed to represent the degree of synchronization among neurons surrounding the electrode. A transient increase in power in a particular band, in response to a behavioral event, is called an event-related synchronization (ERS), while a transient decrease in power is called event-related desynchronization (ERD). ERD and ERS are typically calculated by averaging the power across time segments and comparing this average to a reference epoch.

Research staff at the University of Minnesota will follow FDA guidelines for software development for the RC+S.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S
Actual Study Start Date :
Sep 1, 2019
Actual Primary Completion Date :
Dec 31, 2020
Actual Study Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Device Implantation

Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system

Device: Medtronic RC+S DBS system
Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system

Outcome Measures

Primary Outcome Measures

  1. Passive and Active Rigidity Quantification [6-months]

    Peak resistive torque integral of resistive torque over the pronation and supination Range of Motion (ROM)

  2. Ballistic Elbow Flexion to a Target: Peak Velocity [6-months]

    Peak velocity

  3. Ballistic Elbow Flexion to a Target: Stop Reaction Time [6-months]

    Stop reaction time

  4. Rapid Alternating Pronation-Supination Movements: RMS [6-months]

    Root Mean Square (RMS)-Displacement RMS

  5. Rapid Alternating Pronation-Supination Movements: Freezing Episodes Duration [6-months]

    Duration of hesitation or arrest (freezing) episodes

  6. Rapid Alternating Pronation-Supination Movements: Freezing Episodes Number [6-months]

    Number of hesitation or arrest (freezing) episodes

  7. Gait: Step length [6-months]

    Step length

  8. Gait: Step Time [6-months]

    Step time

  9. Gait: Double Support Time [6-months]

    Double support time

  10. Gait: Obstacles [6-months]

    Percentage of obstacles successfully avoided

  11. Gait: Freezing Episodes Duration [6-months]

    Duration of freezing episodes

  12. Gait: Freezing Episodes Number [6-months]

    Number of freezing episodes

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of idiopathic PD.

  • Age 45-75 years

  • Demonstrated good response (≥ 30%) to Sinemet or dopamine agonist medications as assessed by total UPDRS III score (off and on meds)

  • Clinical plan for unilateral STN- or GPi-DBS surgery to treat their clinical motor signs within the next four months

  • Written documentation of willingness to participate in the study per protocol as evidenced by the informed consent process

Exclusion Criteria:
  • Clinically significant medical disease that would increase the risk of developing pre- or post-operative complications (e.g., major cardiac or pulmonary disease)

  • Evidence of secondary or atypical parkinsonism

  • Dementia as evidenced by impairment in two neuropsychological domains and impaired or borderline neuropsychological function in one additional domain.

  • Unable to undergo MR imaging (e.g., due to incompatible implanted pacemaker)

  • Previous pallidotomy or DBS surgery

  • Women who are currently pregnant

  • MRI brain abnormalities that could indicate a neurological disorder other than idiopathic Lewy body Parkinson's disease.

  • Subjects with severe or poorly controlled depression defined according to DSM-V criteria and a scored on a validated depression assessment scale.

  • Epilepsy

  • Immunocompromised

  • Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) to treat a chronic condition

  • Has an implanted electronic device such as a neurostimulator, cardiac pacemaker or medication pump.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Minnesota Minneapolis Minnesota United States 55455

Sponsors and Collaborators

  • University of Minnesota

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Minnesota
ClinicalTrials.gov Identifier:
NCT04011449
Other Study ID Numbers:
  • NEUR-2019-27724
First Posted:
Jul 8, 2019
Last Update Posted:
Apr 9, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 9, 2021